Form 8-K IVERIC bio, Inc. For: Sep 06
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Stifel Reiterates Buy Rating on Iveric Bio (ISEE) as Zimura 'Checks All Efficacy AND Safety Boxes'
September 6, 2022 12:14 PM EDTStifel analyst Annabel Samimy reiterated a Buy rating and $28.00 price target on Iveric Bio (NASDAQ: ISEE) following the release of GATHER-2 (G2) Zimura data that hit high statistical significance on its primary endpoint of mean rate of GA growth (slope) for both square root transformation and... More
Iveric Bio (ISEE) PT Raised to $27 at Credit Suisse
September 6, 2022 10:33 AM EDTCredit Suisse analyst Tiago Fauth raised the price target on Iveric Bio (NASDAQ: ISEE) to $27.00 (from $24.00) while maintaining a Outperform rating.
The analyst comments "Competitive Dynamic Nuanced, but Valuation Gap Still Favors ISEE Shares. We expect the debate to now shift to... More
Apellis Pharmaceuticals (APLS) weakness appears related to data from IVERIC bio (ISEE) in geographic atrophy
September 6, 2022 8:24 AM EDTApellis Pharmaceuticals (NASDAQ: APLS) weakness appears related to data from IVERIC bio (NASDAQ: ISEE) in geographic atrophy
lSEE +28%APLS -4.3%... MoreGuggenheim on Iveric Bio (ISEE) Gather 2: 'We Expect Approval'
September 6, 2022 7:32 AM EDTGuggenheim analyst Eddie Hickman reiterated a Buy rating on Iveric Bio (NASDAQ: ISEE).
The analyst comments "This morning, ISEE announced that GATHER 2 met its primary endpoint showing a 14.3% reduction in mean rate of growth (slope) over 12 months (reduction was 17.7% was used using observed GA area. We note that while the drug... More
